ilmscore | U.S. Tariffs Shock Indian Pharma | NIFTY Below Key Support level | CA Rachana Ranade

U.S. Tariffs Shock Indian Pharma | NIFTY Below Key Support level | CA Rachana Ranade

Published: 2025-09-26
Status: Available | Analyzed

Predictions from this Video

Total: 5
Correct: 1
Incorrect: 2
Pending: 2
Unrated: 0
Prediction
Topic
Status
Starting October 1, 2025, a 100% tariff will be imposed on branded or patented pharmaceutical products from India unless manufacturing plants are being built in India.
"starting October 1st 2025 we will be imposing a 100% tariff on any branded or patented pharmaceutical products unless a company is building their pharmaceutical manufacturing plants in India"
US Pharma Tariffs
Incorrect
Pharmaceutical products will be exempt from tariffs if construction of manufacturing plants in the US has started.
"there will be no tariffs on these pharmaceutical products if construction has started."
US Pharma Tariffs
Pending
Indian pharmaceutical exports to the USA reached $8.72 billion in 2024.
"2024 only pharma exports only to USA was 8.72 billion."
Indian Pharma Exports to US
Incorrect
US government is investigating under Section 232 whether pharma imports pose a national security threat, creating uncertainty over tariffs.
"Companies still face uncertainty over tariffs due to an investigation order by the US government under section 232 to see whether pharma imports pose a threat to national security."
US Pharma Tariffs Investigation
Correct
There is a possibility of further clarifications from Donald Trump regarding the pharma tariffs, and until then, the pharma sector is expected to remain under negative sentiment.
"he may come up with certain clarifications as well but as of now what we know is that the pharma sector is now pushed into a negative sentiment until and unless few more clarifications come up"
Donald Trump Policy Clarity
Pending